Indegene IPO Subscribed 1.67 Times on Day 1
May 06, 2024 17:52
Indegene's IPO received 1.67 times subscription on Day 1, with strong interest from non-institutional investors. Learn more about the IPO details and key investors.
Illustration: Dominic Xavier/Rediff.com
New Delhi, May 6 (PTI) The initial public offer of healthcare tech firm Indegene got subscribed by 1.67 times on the first day of bidding on Monday.
The Rs 1,841.75 crore IPO received bids for 4,80,93,837 shares against 2,88,66,677 shares on offer, as per NSE data.
The category for non institutional investors received 4.13 times subscription, while the portion for Retail Individual Investors (RIIs) got subscribed 1.50 times. The quota meant for Qualified Institutional Buyers (QIBs) garnered 5 per cent subscription.
The Initial Public Offer (IPO) has a fresh issue of up to Rs 760 crore and an offer for sale of up to 2,39,32,732 equity shares.
The price range for the offer is Rs 430-452 a share.
On Friday, Indegene Ltd said it raised Rs 549 crore from anchor investors.
The OFS would see the sale of shares by existing investors CA Dawn Investments, a Carlyle group entity, Vida Trustees in its capacity as a partner of Group Life Spring, Brighton Park Capital's entities BPC Genesis Fund I SPV Ltd, and BPC Genesis Fund I-A SPV Ltd, and individual investors Manish Gupta, Rajesh Bhaskaran Nair, and Anita Nair.
At present, Nadathur Fareast Pte Ltd is the biggest shareholder in Indegene with a 23.64 per cent stake. CA Dawn Investments has a 20.42 per cent stake, and Brighton Park Capital owns a 12 per cent stake in the company.
Funds raised through the fresh issue would be used to pay the debt, fund capital expenditure requirements, payment of deferred consideration for one of its past acquisitions, fund inorganic growth and general corporate purposes.
Kotak Mahindra Capital Company, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are the managers to the offer.
Founded in 1998, Indegene offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales throughout their life cycle.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
MORE NEWS
TCS Appoints Sudeep Kunnumal as Chief HR Officer
TCS announced Sudeep Kunnumal as the new Chief Human Resources Officer, succeeding...
ICAI to Review IndusInd Bank Financials Amid...
The ICAI may review IndusInd Bank's financial statements after discrepancies in...
India Assures Exporters Protection Amid US...
India's commerce ministry has assured exporters of protection against US tariff...
HDFC Mutual Fund Increases IndusInd Bank Stake...
HDFC Mutual Fund has increased its stake in IndusInd Bank to over 5%, buying 15.92 lakh...
TN Budget 2025-26: Thangam Thennarasu to...
Tamil Nadu Finance Minister Thangam Thennarasu will present the fifth Budget of the DMK...
Starlink India Tie-Ups: Satcom Complementing...
Citi report analyzes Starlink's tie-ups with Jio and Bharti, suggesting satcom services...
SpiceJet Promoter Sells 1% Stake for Rs 52 Crore
Ajay Singh, SpiceJet's MD, has sold nearly 1% stake in the budget airline for Rs 52...
LG Electronics India IPO Approved by Sebi - Rs...
LG Electronics India gets Sebi's nod to float a Rs 15,000 crore IPO, marking the second...
Patanjali, DS Group Acquire Magma General...
Patanjali Ayurved and DS Group will acquire Magma General Insurance from Sanoti...
Canara Bank to Raise Rs 4,000 cr via Tier II Bonds
Canara Bank proposes to raise up to Rs 4,000 crore through Basel III compliant Tier II...
Read More »